Group 1 - The stock price of药捷安康 (02617.HK) experienced significant volatility on September 16, with an intraday increase of over 60% followed by a decline of 53.73%, closing at 192 HKD per share and a total market capitalization of 762 billion HKD [1] - From September 11 to 15, the stock saw a cumulative increase of 361.11%, with a notable rise of 115.58% on September 15 [1] -药捷安康 is a biopharmaceutical company focused on developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases, currently in the clinical registration phase [1] Group 2 - The company has not yet achieved commercialization, with projected losses of 343 million CNY and 275 million CNY for the years 2023 and 2024, respectively [2] - In the first half of the year, the company reported zero revenue and a loss of 123 million CNY [2] - On September 10, the company announced that its core product, Tinengotinib (TT-00420), received clinical approval for a Phase II trial for a specific type of breast cancer [1]
收盘大跌53.73%！盘中一度涨超60%，药捷安康股价高台跳水